Expediting timelines and enhancing quality for global study startup

For drug development sponsors running global studies, each day counts on the path to market. To help support sponsors with a faster study startup, Covance Central Laboratory Services (CLS) has enhanced its core systems and technologies to significantly trim typical startup timelines, reduce the time to implement potential study modifications …

COVID

The COVID-19 road to recovery: coordinating clinical trial testing and central lab solutions

As COVID-19 was declared a pandemic, Covance Clinical Trials Testing Solutions (CTTS) witnessed a sudden influx of COVID-19 studies from both large pharmaceutical organizations and biotechs. Not only did CTTS need to accelerate the timelines for these drug development sponsors’ urgent studies, but they needed to provide patient-centric testing solutions, …

ican peds

Protecting the safety of pediatric clinical trial participants during a pandemic

As clinical trials worldwide are facing unprecedented challenges with the COVID-19 pandemic, the experts working at the regulatory bodies and pharmaceutical companies and staff working at contract research organizations (CRO), such as Covance, have a focus to maintain patient safety as a top priority.  Almost overnight we saw many hospitals …

Patient Centricity

Inflammatory Bowel Disease clinical studies and the importance of patient centricity

In today’s exceptionally crowded clinical trial environment of inflammatory bowel disease (IBD), patient-centric practices can help your study of Crohn’s disease (CD) or ulcerative colitis (UC) stand out to both patients and sites. Learn about your options to increase your trial’s patient centricity, encourage recruitment and promote ongoing patient retention. …

Covance becomes first major central laboratory in Japan to add anatomic pathology and histology services

In an effort to support development of today’s novel therapies and help clients get faster clinical trial results, Covance recently expanded its Asia-Pacific footprint by becoming the first major central laboratory in Japan to add anatomic pathology and histology (APH) services at its Kawagoe facility. Learn more about how this …

Closing the knowledge gap with Real-World Evidence (RWE) studies: the importance of starting early

Successfully demonstrating product safety and efficacy in a randomized clinical trial is a monumental event, but it doesn’t always translate to market access and uptake one it’s launched. Since clinical trials are limited to a controlled sub-set of patients, observations recorded in the clinical trial setting can vary from what …

Brexit: leveraging the mutual recognition agreement to mitigate risk with commercial drug product release testing

The Brexit1 deadline has been extended once again – now to January 31, 2020 – and a withdrawal deal seems likely given the result of the December 12 general election. However, drug manufacturers and contract test laboratories should be proactive in understanding the potential regulatory considerations relating to commercial drug product …

Listening to – and learning from – the voice of the patient

Patient recruitment represents the biggest challenge in clinical trials. From general patient identification and participation to reducing screen failure rate or limiting patient drop out after enrollment, drug developers face many massive pain points to initiate their clinical trials.   Patient recruitment and retention continue to be the biggest challenge in …